Vanguard Global Advisers’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
Other funds holding AMLX
SVCM
Vanguard Global Advisers's AMLX Position: Q3 2026 in Review
Vanguard Global Advisers increased its Amylyx Pharmaceuticals (AMLX) stake by 14% in Q3 2026, buying an estimated $174K and bringing the position to 54,415 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1409.
Vanguard Global Advisers first reported a position in AMLX in Q1 2026 and has held it in 3 quarters since. 229 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.
- Vanguard Global Advisers held 54,415 shares of Amylyx Pharmaceuticals worth $1.58M as of Q3 2026.
- Vanguard Global Advisers bought 6,564 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $174K.
- Amylyx Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1409 holding.
- Vanguard Global Advisers first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- 229 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.